Overview of the EQ-5D Purpose and origins of the descriptive system.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

HEA PTP: M207 Health Economics1 Measurement & Valuation of Health What is health? Why do we need to measure it? How can it be measured? Why do we need.
Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
Quality of life in relation to costs
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Big Q and Little Q revisited Christopher McCabe PhD Capital Health Endowed Research Chair in Emergency Medicine Research.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Health Economics II –2010 Health Economic Evaluations Part III Lecture 2 Cost-effectiveness analysis QALYs and cost-utility analysis Nils-Olov Stålhammar.
QALYs and Ethics Prof. dr. Jan van Busschbach 11.
Quality of life Assessment introduction
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
QALYs and Ethics Is there an ethical / valid alternative?
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Measuring the “Q” in QALYs for cost- effectiveness analysis: the EuroQol Group’s approach Valuing health outcomes for healthcare decision making using.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
Rescuing Clinical Trial Data For Economic Evaluation
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
New and ongoing areas of research In the EuroQol Group.
EQ-5D AND QUALITY OF LIFE OF OSTEOPOROSIS AT-RISK PATIENTS IN A SWEDISH OSTEOPOROSIS PATIENT REGISTRY Arun Krishna 1, Dan Mellström 2, Zhiyi Li 3, Chun-Po.
1 Patient values or values from the general public.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Quality Adjusted Life Years (QALY)
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
The experience of Denmark with Summary Measures of Population Health 7 th Meeting of the Task Force on Health Expectancies Luxembourg, 2 December 2008.
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
Introduction to decision analysis Jouni Tuomisto THL.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Introduction to decision analysis Jouni Tuomisto THL.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO Floor van Nooten, Xander Koolman, Werner Brouwer 1 A paper introduced.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
Canadian TTO Valuations of the EQ-5D-5L: East versus West Differences
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
M. Dakoutrou, V. Gerovasili, G. Sidiras, I. Patsaki, A. Kouvarakos, S
Patient Baseline Assessment
Prof. Dr. Jan J.V. Busschbach
The valuation of disease-specific questionnaires for QALY analysis
Is healthcare any good for patients
Measuring outcomes Emma Frew October 2012.
How to Measure Quality of Life
Presentation transcript:

Overview of the EQ-5D Purpose and origins of the descriptive system

Health Economics Comparing different allocations –Should we spent our money on Wheel chairs Screening for cancer –Comparing costs –Comparing outcome Outcomes must be comparable –Make a generic outcome measure

Outcomes in health economics Specific outcome are incompatible –Allow only for comparisons within the specific field Clinical successes: successful operation, total cure Clinical failures: “events” –“Hart failure” versus “second psychosis” Generic outcome are compatible –Allow for comparisons between fields Life years Quality of life Most generic outcome –Quality adjusted life year (QALY)

Example –Blindness –Time trade-off value is 0.5 –Life span = 80 years –0.5 x 80 = 40 QALYs Quality Adjusted Life Years (QALY) X Life years x 80 = 40 QALYs

Area under the curve

Burden of disease (WHO): QALY lost = DALY Disability adjusted life year DALY QALY

QALY league table

Citations in PubMed

In search of a QoL value… Most controversy about QoL measure –In QALY analysis Uni-dimensional value –Like temperature –Like the IQ-test measures intelligence Ratio or interval scale –Difference 0.00 and 0.80… –… must be 8 time higher than 0.10

Unidimensional, ratio scales Two popular methods have these pretensions –Time trade-off –Standard gamble Two methods are less clear…. –Visual analog scale –Paired comparison Conjoint analysis; DCE, etc

The Rosser & Kind Index

The Rosser & Kind index One of the oldest valuation 1978: Magnitude estimation –Magnitude estimation  PTO –N = 70: Doctors, nurses, patients and general public 1982: Transformation to “utilities” –Other word for “value of QoL”

1985: High impact article

–Survey at the celebration of 25 years of health economics in the UK (HESG): chosen most influential article on health economics

Criticism on the Matrix Sensitivity –only 30 health states The compression of states in the high values The unclear meaning of “distress” The involvement of medical personnel No clear way how to classify the patients –into the matrix Only British values

Value compression

New initiatives Higher sensitivity (more then 30 states) More and better defined dimensions Other valuation techniques –Standard Gamble, Time Trade-Off, Visual Analogue Scale Values of the general public A questionnaire… –to allow patients to ‘self classify’ themselves An international standard –to allow international comparisons –That is at that time “Europe”

EuroQoL Group First meeting 1987 Participants from –UK, Finland, Sweden, The Netherlands A common core instrument –To allow international comparisons –To allow linking of international results Instrument should be small Suitable for sever ill patients –The emerging of high tech medicine, especially transplantation

The first EuroQol Higher sensitivity (more then 30 states) –216 states More and better defined dimensions –6 dimensions –Mobility; –Daily activity and self care; –Work performance –Family and leisure performance –Pain/discomfort –Present mood Other valuation techniques –Visual Analogue Scale

The first EuroQol Values of the general public –Values from general public –But also values from patients (!) A questionnaire –to allow patients to ‘self classify’ themselves A international standard –to allow international comparisons –That is at that time “Europe”

Direct utility assessment

Indirect utility assessment

First indirect values Add the value of death

First international comparisons in 1988 with EQ-6D and VAS

EQ-5D-3L Value Sets TTO Value SetsVAS Value Sets Health State Value Health State

Why indirect utility measures? Original: To avoid ‘strategic responses’ –Patients pressure groups To avoid coping –Underestimating the value of health To allow complex utility assessments –Time Trade Off –Standard Gamble –Willingness to pay –Person Trade off –Paired comparisons (DCE) To allow for societal values of health states –Like costs: the societal perspective

Why indirect utility measures? Original: To avoid ‘strategic responses’ –Patients pressure groups To avoid coping –Underestimating the value of health To allow complex utility assessments –Time Trade Off –Standard Gamble –Willingness to pay –Person Trade off –Paired comparisons (DCE) To allow for societal values of health states –Like costs: the societal perspective

Coping: can be a problem in the patient perspective…. Stensman –Scan J Rehab Med 1985;17: Scores on a visual analogue scale –36 subjects in a wheelchair –36 normal matched controls Mean score –Wheelchair: 8.0 –Health controls: 8.3 Need for indirect valuation Healthy Death

Why indirect utility measures? Original: To avoid ‘strategic responses’ –Patients pressure groups To avoid coping –Underestimating the value of health To allow complex utility assessments –Time Trade Off –Standard Gamble –Willingness to pay –Person Trade off –Paired comparisons (DCE) To allow for societal values of health states –Like costs: the societal perspective

Time Trade-Off TTO: alternative for VAS Wheelchair –With a life expectancy: 50 years How many years would you trade-off for a cure? –Max. trade-off is 10 years QALY(wheel) = QALY(healthy) –Y * V(wheel) = Y * V(healthy) –50 V(wheel) = 40 * 1 V(wheel) =.80

Health economics prefer TTO Visual analogue scale –No trade-off: no relation to QALY No interval proportions –Easy Time trade-Off –Trade-off: clear relation to QALY Interval proportions –Less easy Time consuming in patients Need for indirect valuation

Why indirect utility measures? Original: To avoid ‘strategic responses’ –Patients pressure groups To avoid coping –Underestimating the value of health To allow complex utility assessments –Time Trade Off –Standard Gamble –Willingness to pay –Person Trade off –Paired comparisons (DCE) To allow for societal values of health states –Like costs: the societal perspective

The economic perspective In a normal market: the consumer values count The patient seems to be the consumer –Thus the values of the patients…. If indeed health care is a normal market… But is it….?

Health care is not a normal market Supply induced demands Government control –Financial support (egalitarian structure) Patient  Consumer –The patient does not pay Consumer = General public –Potential patients are paying Health care is an insurance market –A compulsory insurance market

Health care is an insurance market Values of benefit in health care have to be judged from a insurance perspective Who values should be used the insurance perspective?

Who determines the payments of unemployment insurance? Civil servant –Knowledge: professional –But suspected for strategical answers more money, less problems identify with unemployed persons The unemployed persons themselves –Knowledge: specific –But suspected for strategical answers General public (politicians) –Knowledge: experience –Payers

Who’s values (of quality of life) should count in the health insurance? Doctors –Knowledge: professional –But suspected for strategical answers See only selection of patient Identification with own patient Patients –Knowledge: disease specific –But suspected for strategical answers –But coping General public –Knowledge: experience –Payers –Like costs: the societal perspective

The general public should be informed… Valuing without knowledge makes no sense –Thyroid Eye Disease Give description of the disease –For instance in terms of the EQ-5D A patient with bilateral thyroid eye disease with upper lid retraction and exophthalmos.

Why indirect utility measures? Original: To avoid ‘strategic responses’ –Patients pressure groups To avoid coping –Underestimating the value of health To allow complex utility assessments –Time Trade Off –Standard Gamble –Willingness to pay –Person Trade off –Paired comparisons (DCE) To allow for societal values of health states –Like costs: the societal perspective

Indirect utility measrue MOBILITY  I have no problems in walking about  I have some problems in walking about  I am confined to bed SELF-CARE  I have no problems with self-care  I have some problems washing or dressing myself  I am unable to wash or dress myself USUAL ACTIVITIES (e.g. work, study, housework family or leisure activities)  I have no problems with performing my usual activities  I have some problems with performing my usual activities  I am unable to perform my usual activities PAIN/DISCOMFORT  I have no pain or discomfort  I have moderate pain or discomfort  I have extreme pain or discomfort ANXIETY/DEPRESSION  I am not anxious or depressed  I am moderately anxious or depressed  I am extremely anxious or depressed

Validated Questionnaires Describe health states Have values from the general public –Rosser Matrix –QWB –15D –HUI Mark 2 –HUI Mark 3 –EuroQol EQ-5D